一项主要研究发现,强效减肥药物Retatrutide不仅能显著减轻肥胖患者的体重,还在两项临床试验中有效缓解了膝关节骨关节炎疼痛 1。数据显示,该药物在改善患者身体功能方面同样表现出积极作用,表明其在治疗肥胖及其并发症上具有双重益处 1。
此外,礼来公司(Eli Lilly)发布了关于Taltz(ixekizumab)与Zepbound(tirzepatide)联合使用的3b期新数据 1。针对患有银屑病关节炎合并肥胖的成年人群,该三年期研究结果显示,联合疗法具有一年的持久疗效,并能改善患者报告结果及代谢指标 1。
A powerful new weight-loss medication known as Retatrutide has demonstrated the ability to significantly reduce body weight while simultaneously alleviating knee pain associated with osteoarthritis, according to findings from two major clinical trials. 1 Beyond pain relief, the drug was also shown to markedly improve physical function in obese patients suffering from this condition. 1 These results highlight a dual benefit of the treatment, addressing both obesity and its related joint complications through emerging clinical data. 1
In separate developments, pharmaceutical company Eli Lilly released new Phase 3b trial data concerning the combination therapy of Taltz (ixekizumab) and Zepbound (tirzepatide). 1 The study focused on adults diagnosed with both psoriatic arthritis and obesity, revealing that the combined treatment maintained durable efficacy over a one-year period. 1 Additionally, patients receiving this regimen experienced improvements in patient-reported outcomes as well as better metabolic results. 1
评论
还没有评论,欢迎留下第一条。